Studies on mice deficient of key markers of Tregs, including IL-10, CTLA-4, GITR, or PD-1 that develop severe immune-related disorders indicate that these molecules are crucial for Treg function in a cancer setting. The gene discussed is TNFRSF18; the disease is cancer.